TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04666675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Upadacitinib
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Upadacitinib
Description: Oral; Tablet
Study: NCT04603612

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Primary TURBT
Description: As shown in (Fig. 1), all patients will be thoroughly evaluated by medical history and physical exam, laboratory investigations, abdominal pelvic ultrasound (US). Then, all patients will be managed by cystoscopy and initial complete TURBT. Patients with benign pathology, non-urothelial carcinoma or muscle invasive disease, will be excluded from the study.~After 4-6 weeks, eligible patients will be appointed for repeat resection TURBT.
Study: NCT02286583

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Microwave Thermography RTM-01-RES
Description: Divide the breast into 3 circles start from the nipple with 1 cm increase in the circle diameter. Divide this circle into 8 points. This makes us detect 24 points in addition to the nipple as fixed point and the tail of the breast as separate point giving total of 26 points.
Study: NCT00902668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lovastatin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: accelerated partial breast irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Study: NCT01967433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01925274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212384
Description: 30 minute IV infusion of PF-05212384 on days 2, 9, 16 and 23 of each cycle. Intra-patient dose escalation will commence with 110mg and will increase depending on tolerability.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: 90 minutes IV infusion of irinotecan 180mg/m\^2 on days 1 and 15 of each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 120 minute IV infusion of cetuximab 400mg/m\^2 on cycle 1 day 1; 60 minute IV infusion of cetuximab on days 8, 15, and 22 of each cycle, and on day 1 of each cycle after cycle 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 90 minutes IV infusion of Irinotecan 180mg/m\^2 on days 1 and 15 of each cycle
Study: NCT00057954

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Photopheresis
Description: Day -7 to -4: Extracorporeal Photopheresis may be given as an outpatient therapy on two consecutive days any time between days -7 to -4. This must be performed on UVAR or XTS photopheresis machines (Therakos, Inc.) according to standard procedure as per manufacturer's guidelines.
Study: NCT02573285

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgeon Preference
Description: Any standard treatment option may be utilized for the treatment of the pneumothorax, including simple aspiration, chest tube placement, or an operation (VATS).
Study: NCT00057954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Day -3, -2: Pentostatin 4 mg/m²/d by continuous IV infusion (Total dose = 8 mg/m²)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI)
Description: Day -1: TBI 400 cGy total dose given in two 200cGy doses. Patients who have received TBI for a previous transplant or radiation as part of previous treatment for a lymphoid malignancy will receive only 200 cGy in 1 dose.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation
Description: Day 0: Infusion of unmanipulated allogeneic bone marrow or stem cells. Minimum cell dose of 2 x 106 CD34 cells/kg recipient and no more than 10 x 10\^6 CD34/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin (CSA)
Description: Cyclosporin A or tacrolimus will be administered according to institutional GVHD prophylaxis protocols. Therapeutic levels will be maintained and patients will be switched to oral agents when they can tolerate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: At day 100 MMF will be introduced at a dose of 250 mg po BID and cyclosporine or tacrolimus will be tapered according to the discretion of the investigator. The dosage will be escalated to a maximum of 2 g/d at the discretion of the attending physician and will be tapered and discontinued at 12 months if there is no active cGVHD. Doses should be given on an empty stomach

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: The dose of Methotrexate is based on the corrected ideal body weight for patients with \> 33% above ideal weight.~Day +1 MTX 15 mg/m² IV push; Day +3 MTX 10 mg/m² IV push (May be omitted if patient develops mouth sores.)
Study: NCT03237832

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARN-6039
Description: Ascending doses per Cohort
Study: NCT00559754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15mg/kg iv on day 1 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 iv on day 1 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy
Description: As prescribed
Study: NCT00333177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation training (CT)
Description: Cognitive remediation training includes computerized cognitive training plus learning skills group.
Study: NCT03095911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: News items without spin
Description: Interpretation of news items without spin
Study: NCT03237832

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARN-6039
Description: Ascending doses per Cohort

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARN-6039
Description: Ascending doses per Cohort

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARN-6039
Description: Ascending doses per Cohort

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARN-6039
Description: Ascending doses per Cohort

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ARN-6039

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ARN-6039

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ARN-6039

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ARN-6039

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ARN-6039
Study: NCT03408496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release
Description: Manual therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle stretching
Description: Muscle stretching

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Medical appointment
Study: NCT03166436

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: radiofrequency ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biliary stenting
Description: biliary stenting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary stenting
Description: biliary stenting
Study: NCT03095950

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: News items with spin
Description: Interpretation of news items with spin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: News items without spin
Description: Interpretation of news items without spin
Study: NCT02376257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 250 mg DCS
Description: Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mg Modafinil
Description: Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug
Study: NCT03346850

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric tube (NGT) feeding
Description: A nasogastric tube goes from the nose to the stomach.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasoduodenal tube (NDT) feeding
Description: A nasoduodenal tube goes from the nose to the duodenum.
Study: NCT01104948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8031

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04440709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain/neural hand exoskeleton (B/NHE)
Description: The brain/neural hand exoskeleton restores hand motor function by translating user's intention into grasping motions
Study: NCT04205162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verafilcon A
Description: Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verafilcon A
Description: Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Etafilcon A
Description: Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Etafilcon A
Description: Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
Study: NCT00684944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRx0014
Description: Gelatin capsule, tid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRx0014
Description: Gelatin capsule, tid
Study: NCT02300987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEE011

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEE011 Placebo
Study: NCT01611415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Oral
Study: NCT03078257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirofiban in PV
Description: a loading dose of 10ug/kg tirofiban is given in 3 min through PV,followed by a maintenance dose of 0.15ug/kg\*min for 48h.~(clopidogrel 600 mg+aspirin( ASA) 300 mg)x1 day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirofiban in IC
Description: a loading dose of 10ug/kg tirofiban is given in 3 min through IC,followed by a maintenance dose of 0.15ug/kg\*min for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antiplatelet thrombolysin
Description: a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: loading dose of 300 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: loading dose of 300 mg aspirin followed by a maintenance dose of 100 mg/d for at least 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: loading dose of 300 mg aspirin followed by a maintenance dose of 100 mg/d for at least 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: loading dose of 300 mg aspirin followed by a maintenance dose of 100 mg/d for at least 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: loading dose of 300 mg aspirin followed by a maintenance dose of 100 mg/d for at least 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: loading dose of 300 mg aspirin followed by a maintenance dose of 100 mg/d for at least 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: loading dose of 600 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: loading dose of 600 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: loading dose of 600 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: loading dose of 600 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days
Study: NCT04611594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fluid restriction
Description: Ingestion of approximately 20 ml / kg of ideal weight,
Study: NCT03934060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: specific strength training
Study: NCT00981227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Description: Scored tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Description: Scored tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Description: Scored tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Description: Scored tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Description: Scored tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral route
Study: NCT00485004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutting balloon
Description: Cutting balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cutting balloon
Description: Cutting balloon

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Description: Sirolimus-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus-eluting stent
Description: Sirolimus-eluting stent
Study: NCT03212378

Intervention type: OTHER
Intervention: percutaneous coronary interventions
Description: Percutaneous coronary intervention.

Intervention type: OTHER
Intervention: percutaneous coronary interventions
Description: Percutaneous coronary intervention.

Intervention type: OTHER
Intervention: percutaneous coronary interventions
Description: Percutaneous coronary intervention.
Study: NCT00891098

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Imaginal exposure
Description: 7 individual sessions of imaginal exposure of trauma memories according to the prolonged exposure treatment manual

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery rescripting
Description: 7 individual sessions of imagery rescripting of trauma memories according to the imagery rescripting and reprocessing therapy manual
Study: NCT01091766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous injection of test solution
Description: test dose consists of 0.2 ml/kg body weight test solution of the assigned drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous injection of test solution
Description: test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
Study: NCT03984578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPEOX/Pembrolizumab
Description: * Oral Capecitabine: 1000mg/m2 twice a day from Day 1 to 14 of a 3-week cycle.~* IV Oxaliplatin: 130mg/m2 on Day 1 of a 3-week cycle.~* Pembrolizumab: IV infusion of 200mg on Day 1 of a 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab alone
Description: IV infusion of 200mg 21 days from the last CAPEOX/Pembrolizumab combination dose.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Performed after all medical intervention.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Performed after all medical intervention.
Study: NCT01532700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab with GSK2110183
Description: * GSK2110183 125mg OD continuously~* Ofatumumab 300mg IV first dose, 2000mg weekly x 7 doses, then 2000mg monthly x 4 doses
Study: NCT03127215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 150 mg tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Physician's choice
Description: treatment according to current guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin 1.1mg/m² infusional solution
Study: NCT02819648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 40 mg prednisolone (two tablets Prednisolone 20 mg, Aventis Intercontinental, Paris, France)
Study: NCT03984578

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Performed after all medical intervention.
Study: NCT01091766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous injection of test solution
Description: test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
Study: NCT01894230

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SLCO1B1*5 allele testing, results reported at randomization
Description: Genetic testing for SLCO1B1\*5 allele and reporting of results to patient and provider at randomization

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: SLCO1B1*5 allele testing, results reported at end of study
Description: Genetic testing for SLCO1B1\*5 allele and reporting of results to patient and provider at end of study

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic testing for SLCO1B1*5 allele
Description: Blood test for SLCO1B1\*5 allele

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Genetic testing for SLCO1B1*5 allele
Description: Blood test for SLCO1B1\*5 allele
Study: NCT01758406

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intracoronary injection
Description: stem cell transplantation

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intracoronary injection of Placebo
Description: Injection of Placebo via coronary arteries in patients with heart failure.
Study: NCT00412204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium bromide
Description: Subjects will be randomized to treatment with tiotropium or placebo. Double-blind medication will be dispensed in HandiHalers to be taken once daily in the morning for 22 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to treatment with tiotropium or placebo. Double-blind medication will be dispensed in HandiHalers to be taken once daily in the morning for 22 days.
Study: NCT01149434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JI-101
Description: JI-101 inhibits angiogenesis, and subsequently tumor growth, by inhibiting three receptor tyrosine kinases: VEGF Receptor Type 2 (VEGFR 2), platelet derived growth factor receptor beta (PDGFR β and Ephrin B4 (EphB4). JI-101 selectively inhibits kinases critical for all three stages of tumor angiogenesis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JI-101
Description: JI-101 inhibits angiogenesis, and subsequently tumor growth, by inhibiting three receptor tyrosine kinases: VEGF Receptor Type 2 (VEGFR 2), platelet derived growth factor receptor beta (PDGFR β and Ephrin B4 (EphB4). JI-101 selectively inhibits kinases critical for all three stages of tumor angiogenesis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus is a signal transduction inhibitor that selectively inhibits mTOR (mammalian target of rapamycin), a key and highly conserved serine-threonine kinase, that is present in all cells and is a central regulator of protein synthesis and ultimately cell growth, cell proliferation, angiogenesis, and cell survival. mTOR is the only currently known target of everolimus (1).
Study: NCT04928664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Single shot injection of 10ml 1.33% LB; Due to the milky colour of LB, syringe containing the LB will be covered; Followed by placement of indwelling catheter in ISB; Catheter will be connected to a fixed-rate portable elastometric pump ( Easy pump, ®) upon arrival in the recovery room by the nurse; The pump will be filled with 300ml NS; The default fixed rate of infusion will be 5ml/hr; Both the pump and the clamp will be covered by an aluminium foil; Catheter and pump will be removed on post-operative day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard bupivacaine
Description: Single shot injection of 10 ml 0.25% SB in ISB; In order to have blinding to the drug injected, syringe containing SB will be covered; followed by placement of indwelling catheter in ISB; Catheter will be connected to a fixed-rate portable elastometric pump ( Easy pump, ®) upon arrival in the recovery room by the nurse; The pump will be filled with 300ml 0.2% SB; The default fixed-rate of infusion will be 5ml/hr; Both the pump and the clamp will be covered by an aluminium foil; Catheter and pump will be removed on post-operative day 2
Study: NCT01848210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coumarin/troxerutin
Description: Coumarin + troxerutin fixed-dose combination tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Coumarin + troxerutin placebo-matching tablets